Skip to Content

Significant PFS Benefit for the Nivolumab + Relatlimab Combination for Patients with Unresectable or Metastatic Melanoma

The dual-checkpoint inhibitor combination of nivolumab and relatlimab continues to provide a significant efficacy benefit over nivolumab alone in patients with previously untreated unresectable or metastatic melanoma according to RELATIVITY-047 update.

Get access

If you are a doctor, nurse, or other health professionals, you can access the entire article by creating a profile on BestPractice Nordic.

Back to top